RMTIRMTIHealthcare · Drug Manufacturers - Specialty & Generic

RMTI Stock Forecast: Rockwell Medical, Inc. Price Predictions for 2026-2027

Last close, 17 Nov 2026
$6.61

The 2 Wall Street analysts covering Rockwell Medical, Inc. hold a median 12-month price target of $20 — +202.6% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 78 of 100 as at 17 Nov 2026 — inside the top quartile. Here, the model and the Street point the same way.

Market cap
$26.3M
Ticker Nerd rank
78/ 100
Median analyst target
$20
Analysts covering
2
Revenue$17.8M+10.6% y/y
Operating income−$1.1M
Net income−$1.2M
Free cash flow$1.5M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Ticker Nerd rank

RMTI stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Rockwell Medical, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 17 Nov 2026
78/ 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Accruals
95
Growth
85
Size
85
Volatility
77
Value
76
Quality
73
Issuance
36
Momentum
33
Revisions
29

Accruals (95): Reported profit is backed by cash, and the company is not expanding recklessly.

Revisions (29): Analysts have, on balance, been cutting their forecasts.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

RMTI stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on RMTI, reported as data — targets and ratings, the market's view beside the model's.

We don’t hold enough price history for this company yet.

What Wall Street says2 analysts
2 Buy0 Hold0 Sell
Low $20Median $20High $20

The green dot is the last close — the median target sits +202.6% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
11 Sept 2026HC Wainwright & Co.ReiteratesBuy$20
9 July 2026HC Wainwright & Co.MaintainsBuy$2.00 → $20
9 July 2026HC Wainwright & Co.MaintainsBuy—
30 Mar 2026HC Wainwright & Co.MaintainsBuy—
26 Jan 2026HC Wainwright & Co.ReiteratesBuy—
13 Nov 2025HC Wainwright & Co.MaintainsBuy—
24 Mar 2025HC Wainwright & Co.MaintainsBuy—
23 Dec 2024HC Wainwright & Co.ReiteratesBuy—
25 Nov 2024HC Wainwright & Co.MaintainsBuy—
14 Nov 2024Rodman & RenshawInitiatesBuy—
11 Sept 2024HC Wainwright & Co.ReiteratesBuy$9.00
4 Sept 2024HC Wainwright & Co.ReiteratesBuy$9.00
12 Aug 2024HC Wainwright & Co.ReiteratesBuy—
16 May 2024HC Wainwright & Co.ReiteratesBuy—
25 Mar 2024HC Wainwright & Co.MaintainsBuy—
15 Nov 2023HC Wainwright & Co.ReiteratesBuy—
5 Oct 2023Maxim GroupInitiatesBuy—
4 Oct 2023HC Wainwright & Co.ReiteratesBuy—
28 Sept 2023HC Wainwright & Co.ReiteratesBuy—
28 Sept 2023HC Wainwright& Co.ReiteratesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

RMTI appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,600 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Estimates

RMTI analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
Analysts raising
0
Analysts cutting
2
Fundamentals

Rockwell Medical, Inc. (RMTI) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−4.7×

Cheaper than 91% of US stocks

Price / sales
0.4×

Cheaper than 83% of US stocks

Price / book
0.7×

Cheaper than 76% of US stocks

EV / EBITDA
−12.4×

Cheaper than 85% of US stocks

Growth & margins
Revenue growth (YoY)
20.1%

Higher than 55% of US stocks

Earnings growth (YoY)
10.6%

Higher than 50% of US stocks

Gross margin
18.2%

Higher than 19% of US stocks

Operating margin
−5.9%

Higher than 27% of US stocks

Net margin
−7.8%

Higher than 21% of US stocks

Returns & dividend
Return on equity
−14.8%

Higher than 33% of US stocks

Return on assets
−9.6%

Higher than 31% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Rockwell Medical, Inc. (RMTI) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Rockwell Medical, Inc. has a market value of $26.3M and an enterprise value of $28.0M.

  • Revenue in the twelve months to 30 June 2026: $69.4M. The latest quarter grew 20.1% year on year.

  • Net income over the same four quarters: −$5.1M, a −7.3% net margin.

  • Diluted earnings per share, trailing twelve months: −$1.34.

  • Free cash flow in the twelve months to 30 June 2026: $1.5M.

  • Shares outstanding: 4.0M.

  • Trailing P/E: −4.7×; forward P/E: 94.4× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Rockwell Medical, Inc. employs 157 people — $442K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 18 Nov 2026

Data provided by Twelve Data

Peers

RMTI vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelDrug Manufacturers - Specialty & Generic
CompanyMarket capTKN rank
RMTIRockwell Medical, Inc.$26.3M78
SCYXSCYNEXIS, Inc.$28.3M36
AYTUAytu Biopharma, Inc.$28.6M96
TXMDTherapeuticsMD, Inc.$22.1M82
CPHIChina Pharma Holdings, Inc.$21.5M48
IXHLIncannex Healthcare, Inc.$20.8M50
SHPHShuttle Pharmaceuticals Holdings, Inc.$20.5M20

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Rockwell Medical, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest RMTI news & analysis

Rockwell Medical, Inc. (RMTI) Q3 2026 Earnings Call Transcript

Seeking Alpha · 12 Nov 2026neutral

Seeking Alpha published the transcript of Rockwell Medical, Inc.’s Q3 2026 earnings call. The excerpt provides no details about the discussion or results.

Why it matters — RMTI watchers may consult the transcript for management commentary, though no specific takeaways are included in the provided excerpt.

Rockwell Medical (RMTI) Reports Q3 Loss, Tops Revenue Estimates

Zacks Investment Research · 12 Nov 2026negative

Rockwell Medical reported a third-quarter loss of $0.59 per share, compared with the Zacks Consensus Estimate of a $0.18 loss and a year-ago loss of $0.50 per share. The headline says revenue topped estimates.

Why it matters — RMTI watchers may note that the reported quarterly loss was larger than the consensus estimate and the year-ago loss.

Rockwell Medical Announces Third Quarter 2026 Results

Business Wire · 12 Nov 2026positive

Rockwell Medical announced its third-quarter 2026 results, reporting that net sales grew 20% year over year. The company attributed the growth to strong customer adoption of its hemodialysis concentrates products.

Why it matters — The reported sales growth and product adoption provide RMTI watchers with an update on the company’s quarterly performance.

Rockwell Medical, Inc. (RMTI) M&A Call Transcript

Seeking Alpha · 3 Nov 2026neutral

Seeking Alpha published a transcript labeled as a Rockwell Medical, Inc. (RMTI) M&A call. The provided excerpt contains no further details about the call.

Why it matters — RMTI watchers may note the publication of an M&A call transcript, but the excerpt does not describe its contents or implications.

FAQ

Frequently asked questions about RMTI stock

What is the RMTI stock price forecast for 2026-2027?

The 2 Wall Street analysts covering Rockwell Medical, Inc. have a median 12-month price target of $20, with estimates ranging from $20 to $20. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is RMTI stock a buy right now?

Of the 2 analysts covering Rockwell Medical, Inc., 2 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Rockwell Medical, Inc. 78 out of 100 across roughly 4,600 US stocks as at 17 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank RMTI?

As at 17 Nov 2026, Rockwell Medical, Inc. ranks 78 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Accruals (95 of 100).

Will RMTI stock go up?

No one can know that. What the data says: the median 12-month target from 2 analysts implies +202.6% from the last close, and Ticker Nerd's factor model ranks Rockwell Medical, Inc. 78 out of 100 as at 17 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the RMTI stock forecast for 2030?

No analyst covering Rockwell Medical, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for RMTI are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $20 to $20 over the next 12 months.

What does Rockwell Medical, Inc. do?

Rockwell Medical Inc. is a healthcare company focused on developing, manufacturing, commercializing, and distributing hemodialysis products for dialysis providers worldwide.

What is the latest news on RMTI?

The most recent item we track (Seeking Alpha, 12 Nov 2026): "Rockwell Medical, Inc. (RMTI) Q3 2026 Earnings Call Transcript". Seeking Alpha published the transcript of Rockwell Medical, Inc.’s Q3 2026 earnings call. The excerpt provides no details about the discussion or results.

Company

About Rockwell Medical, Inc.

Rockwell Medical Inc. is a healthcare company focused on developing, manufacturing, commercializing, and distributing hemodialysis products for dialysis providers worldwide. Its portfolio centers on liquid and dry acid and bicarbonate concentrates, along with related mixers and ancillary supplies used in dialysis treatment. The company serves outpatient dialysis centers, hospital-based facilities, skilled nursing settings, and home care environments, supporting the day-to-day delivery of kidney care. Rockwell Medical’s products are designed to help maintain the dialysis process by removing toxins and balancing electrolytes in patients with end-stage kidney disease. The company operates manufacturing and distribution capabilities that support customers in the United States and international markets, making it an important supplier within the renal care and dialysis supply chain. Headquartered in Wixom, Michigan, Rockwell Medical continues to focus on specialized products and services for the hemodialysis market.

CEO Dr. Mark Strobeck Ph.D. · 157 employees · United States · https://www.rockwellmed.com